OIS: Ophthalmology Innovation & Investment – ReNeuron using hRPCs to treat inherited retinal degenerative diseases
Proactive Investors ‘ReNeuron focus on new clinical trials’
Proactive investors ‘Breakthrough to open up potential new revenue opportunities for Reneuron Plc’
Proactive Investors: Michael Hunt discusses very encouraging long-term stroke data
https://www.youtube.com/watch?v=7R4JluRuyKE
2017 AGM Trading Update – Shareholder Presentation
September 2017: Please click here to see the slides accompanying the AGM Trading Update presentation.
Proactive Investors: ReNeuron gears up for Phase III stroke disability study
https://youtu.be/QJaKk3F-TQs
Preliminary results presentation webcast 2017
Please click on link below for the webcast of the 2017 preliminary results presentation.
Proactive Investors: ReNeuron ‘greatly encouraged’ by US regulator feedback on CTX cell therapy trial
To view the full article click here…
Proactive Investors: CFO discusses very significant exosome therapy data
To view the full article please click here…